AI vs Radiologists in Prostate Cancer Detection: Insights from the PI-CAI International Study.

10-Year Trial: Laparoscopic vs Robot-Assisted Radical Prostatectomy Outcomes

MRI vs PSMA-PET: Predicting Prostate Cancer Extension & Surgical Guidance Trial

Radical Prostatectomy Without Biopsy: Insights from PSMA-PET/CT & MRI Trial

Phase 3 Trial: Stereotactic Body Radiotherapy in Localized Prostate Cancer (NEJM 2024)

Hypo-FLAME Trial: 5-Year Outcomes of SBRT with Focal Boost in Prostate Cancer (2024)

HYPO-RT-PC Trial: Long-Term Morbidity After Prostate Ultra-Hypofractionation

Panel Discussion: Key Insights from Recent Prostate Cancer Clinical Trials & Studies

Pelvic Lymph Node Dissection in Prostate Cancer: Limited vs Extended Trial Update

Trifecta Outcomes with 3D Digital Models in Robotic Prostatectomy: Trial Analysis

RE-START Study: Re-SBRT After Definitive or Salvage Radiotherapy in Prostate Cancer

PACE-A Trial: Radical Prostatectomy vs Stereotactic Radiotherapy in Localised Prostate Cancer

ASCO-GU 2025: Radical Prostatectomy vs Radiotherapy in High-Risk Prostate Cancer (IPD Study)

ESMO 2024: Transdermal Estradiol vs LHRH Agonists in M0 Prostate Cancer (Phase 3 Trial)

PARTIQoL Trial: Proton Therapy vs IMRT in Localized Prostate Cancer (Phase III Results)

PORTOS Gene Signature: Predicting Dose-Response to Prostate Radiation in Phase III Trials

Panel Discussion: Advances & Insights from Recent Prostate Cancer Trials and Research

Darolutamide + ADT in Metastatic Hormone-Sensitive Prostate Cancer: Phase III ARANOTE Trial.

ASCO GU 2025: STOPCAP Meta-Analysis on AR Pathway Inhibitors in mHSPC Patients

ASCO 2024: PLATIPARP Trial – Induction Chemo + Rucaparib in HRR-Deficient mCRPC

ASCO GU 2025: Docetaxel Rechallenge vs Cabazitaxel in Previously Treated mCRPC Patients

ASCO GU 2025: Extended Interval Dosing of Denosumab in Metastatic Prostate Cancer Patients

ENZA-p Trial: [177Lu]Lu-PSMA-617 + Enzalutamide vs Enzalutamide in mCRPC – Survival & QoL

ASCO GU 2025: Exercise Program to Reduce Fatigue in Advanced Prostate Cancer on ADT

ASCO GU 2025: GROUQ-PCS9 Trial – Metastases-Directed Therapy in Oligometastatic mCRPC

Panel Discussion: Key Insights on Prostate Cancer Clinical Trials & Abstracts

Enfortumab Vedotin in Relapsed/Refractory Bladder Cancer: Clinical Outcomes & Advances

Phase 3 Trial: [89Zr]Zr-Girentuximab PET-CT Imaging in Clear-Cell Renal Cell Carcinoma

Cryoablation vs Robotic Partial Nephrectomy in cT1 Renal Tumors: Systematic Review & Meta-Analysis

Positive Surgical Margins in Localized Renal Cell Carcinoma: Predictors & Survival Impact

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival Outcomes (NEJM Study)

Panel Discussion: Key Advances in Renal Cell Carcinoma from Recent Clinical Trials & Studies

Upfront vs Deferred Cytoreductive Nephrectomy in Metastatic RCC: Systematic Review & Meta-Analysis

ASCO GU 2025: SABR with TKI & IO Therapy in Metastatic Renal Cell Carcinoma – Efficacy & Safety

ASCO GU 2025: CALYPSO Trial – Final OS & ctDNA Analysis in MET-Driven Papillary Renal Cancer

RENOTORCH Phase III: Toripalimab + Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma

CheckMate 9ER: Extended Follow-Up of Nivolumab + Cabozantinib vs Sunitinib in Advanced RCC

CheckMate 214: 8-Year Follow-Up of Nivolumab + Ipilimumab vs Sunitinib in Advanced RCC

Panel Discussion: Long-Term Immunotherapy & Targeted Therapy Advances in Renal Cell Carcinoma

Case-Based Panel: Peri-Operative Immunotherapy in Muscle-Invasive Bladder Cancer (MIBC)

CAR-T Cell Therapy: Advances, Applications & Future Directions in Cancer Treatment

Conquering Challenging Cases in mCSPC & mCRPC: Expert Insights in Prostate Cancer Care

Panel Discussion: Role of Patient Advocacy in Improving Life & Quality for Bladder Cancer Patients

AI vs Radiologists in Prostate Cancer Detection: Insights from the PI-CAI International Study.

10-Year Trial: Laparoscopic vs Robot-Assisted Radical Prostatectomy Outcomes

MRI vs PSMA-PET: Predicting Prostate Cancer Extension & Surgical Guidance Trial

Radical Prostatectomy Without Biopsy: Insights from PSMA-PET/CT & MRI Trial

Phase 3 Trial: Stereotactic Body Radiotherapy in Localized Prostate Cancer (NEJM 2024)

Hypo-FLAME Trial: 5-Year Outcomes of SBRT with Focal Boost in Prostate Cancer (2024)

HYPO-RT-PC Trial: Long-Term Morbidity After Prostate Ultra-Hypofractionation

Panel Discussion: Key Insights from Recent Prostate Cancer Clinical Trials & Studies

Pelvic Lymph Node Dissection in Prostate Cancer: Limited vs Extended Trial Update

Trifecta Outcomes with 3D Digital Models in Robotic Prostatectomy: Trial Analysis

RE-START Study: Re-SBRT After Definitive or Salvage Radiotherapy in Prostate Cancer

PACE-A Trial: Radical Prostatectomy vs Stereotactic Radiotherapy in Localised Prostate Cancer

ASCO-GU 2025: Radical Prostatectomy vs Radiotherapy in High-Risk Prostate Cancer (IPD Study)

ESMO 2024: Transdermal Estradiol vs LHRH Agonists in M0 Prostate Cancer (Phase 3 Trial)

PARTIQoL Trial: Proton Therapy vs IMRT in Localized Prostate Cancer (Phase III Results)

PORTOS Gene Signature: Predicting Dose-Response to Prostate Radiation in Phase III Trials

Panel Discussion: Advances & Insights from Recent Prostate Cancer Trials and Research